/PRNewswire/ Novo Holdings REPAIR Impact Fund today announces that it has participated in the EUR 72 million financing of MinervaX, a privately held Danish.
Novo Seeds Portfolio Company, IO Biotech, Completes Oversubscribed EUR 127M Series B Financing to Accelerate Clinical Programs in Oncology
- IO Biotech to accelerate the development of novel, immune-modulating anti-cancer therapies based on its proprietary T-win® technology
- Novo Seeds created and launched IO Biotech with first seed investment in 2015
- Participated in further financing alongside a strong syndicate of investors
News provided by
Share this article
Share this article
COPENHAGEN, Denmark, Jan. 13, 2021 /PRNewswire/ Novo Seeds, the early-stage investment and company creation team of Novo Holdings, announced today that its portfolio company, IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune-modulating anti-cancer therapies based on its proprietary T-win® technology, has raised EUR 127 million in Series B financing.
Novo Seeds Portfolio Company CorWave Raises EUR 35 Million for Breakthrough Heart Pump
- Existing syndicate joined by the EIC Fund, a multi-billion-euro venture capital fund set up by the European Commission that becomes shareholder of a private company for the first time
- Funding will accelerate development of wave membrane pump into heart failure clinical trials
News provided by
Share this article
Share this article
COPENHAGEN, Denmark, Jan. 6, 2021 /PRNewswire/ Novo Seeds, the early stage investment and company creation team of Novo Holdings, announced today that its portfolio company CorWave, a medtech company developing an implantable heart pump based on a breakthrough technology, has raised EUR 35 million in a Series C financing.
Share:
COPENHAGEN, Denmark, Dec. 15, 2020 /PRNewswire/ MinervaX, a privately held Danish biotechnology company developing a novel vaccine against Group B Streptococcus (GBS), announced today that it has raised an upsized EUR 47.4 million Series B financing. The round included new investors Sanofi Ventures, Wellington Partners, Adjuvant Capital, and Industrifonden, along with existing investors Novo Holdings REPAIR Impact Fund, Sunstone Life Science Ventures, and LF Investment. Proceeds will advance the clinical development of MinervaX s novel GBS vaccine through Phase II clinical trials, as well as manufacturing and regulatory preparation for Phase III.
Concurrent with the financing, Christopher Gagliardi from Sanofi Ventures, Karl Nägler from Wellington Partners, Kabeer Aziz from Adjuvant Capital and Bita Sehat from Industrifonden will join MinervaX s board of directors.
(1)
-
On the back of highly promising Phase Ib data, MinervaX has raised financing from leading investors to accelerate development of its novel vaccine through the end of Phase II trials and preparations for Phase III pivotal trials
-
Novel vaccine candidate offers viable alternative to antibiotics, thereby strategically aligned with REPAIR Impact Fund s mission to combat antimicrobial resistance (AMR)
-
-
Group B Streptococcus (GBS) is one of the leading causes of stillbirth and infant mortality representing a significant unmet need globally, including in the US and Europe; nearly one in five women globally are colonized by GBS
COPENHAGEN, Denmark, Dec. 15, 2020 /PRNewswire/ Today, the Novo Holdings REPAIR Impact Fund announces a further investment in MinervaX, a privately held Danish biotechnology company developing a novel vaccine against Group B Streptococcus (GBS), renewing its commitment to the company following two tranches of investment in 2018 and 2019. Initi